Platform & MSO Finance
RCM Performance Metrics for Multi-Site Infusion Platforms
Payer policy shifts now pose bigger revenue risks than staffing for infusion platforms.
Jerome Castellano
· 9 min read
Buy and Bill Brief — Page 3
Revenue per Infusion Benchmarks for Independent Infusion Groups
Revenue per infusion exposes billing breakdowns that volume metrics mask.
Renata Szymborska
Prior Authorization Failure as a Drug Cost Liability Event
Prior authorization denials in buy-and-bill infusion create unrecoverable financial losses.
Darius Okonkwo
J-Code Billing Errors That Trigger Biologic Denials
How to avoid the five most expensive J-code mistakes that tank biologic claims.
Jerome Castellano
Biosimilar Substitution Financial Risk in Buy-and-Bill
Biosimilar competition is collapsing reimbursement faster than practices can adjust.
Darius Okonkwo
Catastrophic Claim Concentration Risk in Small Infusion Groups
One denial on a five-figure drug claim can erase an entire month's margin for small infusion groups.
Renata Szymborska
Drug Waste Billing Compliance in Infusion Reimbursement
Misclassifying vials costs practices through denials with no recovery path.
Renata Szymborska
Underpayment vs Denial Risk in Biologic Claims
Denial and underpayment require different strategies to protect biologic revenue.
Darius Okonkwo